Oramed Pharmaceuticals (ORMP)
NASDAQ:ORMP
Top Page
Oramed Pharm
(NASDAQ:ORMP)
Select Model
Select Model
Rating:61Neutral
Price Target:
$3.50
▲(20.27% Upside)
Action:ReiteratedDate:04/01/26
The score is held back primarily by persistently negative operating profitability and cash burn despite a strong, low-debt balance sheet. Offsetting that, valuation looks very cheap (low P/E and high yield) and corporate actions (asset monetization/strategic deals and a dividend) are supportive, while technicals are mixed with only modest momentum.
Positive Factors
Balance sheet strength
Very low leverage and sizable equity give Oramed enduring financial flexibility to fund R&D, manage trials, and execute strategic deals without immediate refinancing pressure. This conserves optionality for partnerships, milestone timing, and shareholder returns over the next several months.
Negative Factors
Consistent cash burn
Persistent negative operating and free cash flow reflects an R&D-intensive, cash-consuming model that will require ongoing financing or asset monetization. Over 2–6 months this raises runway and dilution risk, constraining the firm's ability to scale without external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low leverage and sizable equity give Oramed enduring financial flexibility to fund R&D, manage trials, and execute strategic deals without immediate refinancing pressure. This conserves optionality for partnerships, milestone timing, and shareholder returns over the next several months.
Read all positive factors
Oramed Pharm (ORMP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$138.33M
Dividend YieldN/A
Average Volume (3M)210.74K
Price to Earnings (P/E)1.6
Beta (1Y)0.61
Revenue GrowthN/A
EPS Growth814.20%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding40,446,180
10 Day Avg. Volume339,860
30 Day Avg. Volume210,739
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)59.00
P/FCF Ratio-12.89
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue46.60
Enterprise Value/Gross Profit7.17K
Enterprise Value/Ebitda-6.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.26
Revenue Forecast (FY)N/A
Oramed Pharm Business Overview & Revenue Model
Company Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is ...
How the Company Makes Money
Oramed has historically generated little to no recurring revenue from product sales because it is a clinical-stage company without an approved commercial product. Its potential and/or actual revenue sources are tied to (1) collaboration and licens...
Oramed Pharm Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Sep 2023 | Dec 2022 | Aug 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.00M | 0.00 | 1.34M | 2.70M | 2.70M |
| Gross Profit | 13.00K | -193.00K | 1.34M | 2.70M | 2.70M |
| EBITDA | -15.09M | -14.87M | 7.32M | -36.98M | -25.04M |
| Net Income | 75.32M | -19.10M | 5.53M | -37.76M | -22.24M |
Balance Sheet | |||||
| Total Assets | 97.59M | 155.28M | 220.55M | 161.64M | 128.00M |
| Cash, Cash Equivalents and Short-Term Investments | 51.36M | 141.93M | 162.05M | 155.72M | 94.14M |
| Total Debt | 825.00K | 372.00K | 51.62M | 894.00K | 533.00K |
| Total Liabilities | 12.03M | 9.93M | 57.66M | 10.49M | 11.48M |
| Stockholders Equity | 199.74M | 146.26M | 163.82M | 151.81M | 115.77M |
Cash Flow | |||||
| Free Cash Flow | -9.15M | -8.43M | -10.55M | -29.20M | -21.56M |
| Operating Cash Flow | -9.14M | -8.41M | -10.29M | -28.70M | -21.18M |
| Investing Cash Flow | 5.44M | 105.82M | -73.04M | 30.21M | -22.26M |
| Financing Cash Flow | -4.74M | -52.04M | 51.98M | 11.56M | 101.39M |
Oramed Pharm Technical Analysis
Positive
2.91
Price Trends
3.40
Negative
3.05
Positive
2.57
Positive
Market Momentum
<0.01
Positive
49.39
Neutral
30.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORMP, the sentiment is Positive. The current price of 2.91 is below the 20-day moving average (MA) of 3.42, below the 50-day MA of 3.40, and above the 200-day MA of 2.57, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 49.39 is Neutral, neither overbought nor oversold. The STOCH value of 30.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORMP.
Oramed Pharm Risk Analysis
Oramed Pharm disclosed 45 risk factors in its most recent earnings report. Oramed Pharm reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oramed Pharm Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $138.33M | 1.57 | 43.14% | ― | ― | 814.20% | |
54 Neutral | $259.27M | -0.60 | -118.95% | ― | ― | 31.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $165.66M | -7.27 | -10.35% | ― | -42.62% | ― | |
47 Neutral | $96.72M | -1.71 | -305.39% | ― | -90.18% | -17.93% | |
40 Underperform | $5.51M | -1.64 | -370.46% | ― | ― | 2.26% |
* Healthcare Sector Average
ORMP
Oramed Pharm
3.42
1.46
74.76%
WHWK
Whitehawk Therapeutics
3.51
1.85
111.45%
QNCX
Quince Therapeutics
0.10
-1.14
-92.02%
ALXO
ALX Oncology Holdings
1.97
1.45
278.85%
SPRB
Spruce Biosciences
70.50
49.46
235.05%
Oramed Pharm Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Oramed Completes Oratech Sale and Strategic Lifeward Financing
Positive
Apr 1, 2026
On March 25, 2026, Lifeward Ltd. completed its previously announced acquisition of Oramed’s wholly owned subsidiary Oratech Pharma, Inc., issuing Oramed more than 1.25 million Lifeward ordinary shares, over 1 million pre-funded warrants, and...
Business Operations and StrategyPrivate Placements and Financing
Oramed Pharmaceuticals Restructures Scilex Notes via Warrant Deal
Positive
Feb 20, 2026
On February 19, 2026, Oramed Pharmaceuticals entered into a Warrant Agreement with Scilex Holding Company, under which Oramed deferred an amortization payment due October 1, 2025 on Scilex’s Tranche B senior secured convertible notes in exch...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Oramed Pharm pivots with Lifeward strategic platform deal
Positive
Jan 14, 2026
On January 12, 2026, Oramed Pharmaceuticals entered into a set of strategic agreements with Lifeward Ltd. under which Oramed will transfer its POD™ oral drug delivery platform, including its investigational oral insulin capsule, to Lifeward ...
Business Operations and StrategyDividendsFinancial Disclosures
Oramed Pharm Announces Dividend After Scilex Payment Gain
Positive
Jan 7, 2026
On January 7, 2026, Oramed Pharmaceuticals reported receiving an $18 million payment from Scilex Holdings Inc., marking full satisfaction of obligations under their Option Agreement and lifting Oramed’s realized returns on its original $99.5...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.